Nuformix is making good progress on the development of NXP002, its novel inhaled form of tranilast intended for idiopathic pulmonary fibrosis (IPF). It is executing a plan designed to generate a phase 1-ready formulation in c. 18 months’ time, when it may be able to seek a licensing partner. IPF is an attractive market opportunity with around ten projects in mid/late-stage clinical trials, only two of which are delivered by inhalation, a route with self-evident advantages in this indication. The ....
